Daiichi Sankyo (OTCMKTS:DSNKY) Raised to Hold at Zacks Research

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks reports.

Separately, Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Two research analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Get Our Latest Research Report on Daiichi Sankyo

Daiichi Sankyo Price Performance

Shares of DSNKY opened at $17.11 on Wednesday. Daiichi Sankyo has a 12-month low of $14.98 and a 12-month high of $24.77. The business’s fifty day moving average is $17.75 and its 200 day moving average is $17.51. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The stock has a market cap of $31.87 billion, a P/E ratio of 17.46, a P/E/G ratio of 1.64 and a beta of -0.10.

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.08. The business had revenue of $3.77 billion during the quarter, compared to the consensus estimate of $3.58 billion. Daiichi Sankyo had a net margin of 12.13% and a return on equity of 16.31%. Sell-side analysts anticipate that Daiichi Sankyo will post 1.05 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).

See Also

Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.